Ronald J. van der Sluis

Dr. Ronald J. van der Sluis

Leiden Academic Centre for Drug Research
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2012 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
RSRonald J. van der Sluis
Ronald J. van der Sluis
GPGijs H. van Puijvelde
Gijs H. van Puijvelde
TBTheo J.C. Van Berkel
Theo J.C. Van Berkel
Menno HoekstraMenno Hoekstra
Menno Hoekstra

1 March 2020 in Molecular and Cellular Endocrinology
Verified
Journal Article
Open access
RSRonald J. van der Sluis
Ronald J. van der Sluis
Menno HoekstraMenno Hoekstra
Menno Hoekstra
Adrenal-derived glucocorticoids mediate the physiological response to stress. Chronic disturbances in glucocorticoid homeostasis, i.e. in Addison's and Cushing's disease patients, predispose to the development of atherosclerotic cardiovascular disease. Here we review preclinical and clinical findings regarding the relation between changes in plasma glucocorticoid levels and the atherosclerosis extent. It appears that, although the altered glucocorticoid function can in most cases be restored in the different patient groups, current therapies do not necessarily reverse the associated risk for atherosclerotic cardiovascular disease. In our opinion much attention should therefore be given to the development of a Cushing's disease mouse model that can (1) effectively replicate the effect of hypercortisolemia on atherosclerosis outcome observed in humans and (2) be used to investigate, in a preclinical setting, the relative impact on atherosclerosis susceptibility of already available (e.g. metyrapone) and potentially novel (i.e. SR-BI activity modulators) therapeutic agents that target the adrenal glucocorticoid output.

1 September 2012 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ZLZhaosha Li
Zhaosha Li
YWYanan Wang
Yanan Wang
RSRonald J. van der Sluis
Ronald J. van der Sluis
JHJosé W.A. van der Hoorn
José W.A. van der Hoorn
HPHans M.G. Princen
Hans M.G. Princen
Menno HoekstraMenno Hoekstra
Menno Hoekstra

1 September 2016 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
RGRick van der Geest
Rick van der Geest
AOAmber B. Ouweneel
Amber B. Ouweneel
RSRonald J. van der Sluis
Ronald J. van der Sluis
AGAlbert K. Groen
Albert K. Groen
MEMiranda Van Eck
Miranda Van Eck
Menno HoekstraMenno Hoekstra
Menno Hoekstra

1 June 2017 in Atherosclerosis
Verified
Journal Article
Open access
AOAmber B. Ouweneel
Amber B. Ouweneel
RSRonald J. van der Sluis
Ronald J. van der Sluis
JNJoya E. Nahon
Joya E. Nahon
MEMiranda Van Eck
Miranda Van Eck
Menno HoekstraMenno Hoekstra
Menno Hoekstra
Statin treatment disrupts HMG-CoA reductase-mediated endogenous cholesterol synthesis and lowers plasma LDL-cholesterol levels. Although statin treatment can theoretically impair adrenal steroid hormone synthesis, thus far, no effect on glucocorticoid output has been described, as LDL-cholesterol levels usually remain within the physiological range. However, novel statin-based treatment regimens that dramatically decrease LDL-cholesterol levels are currently employed. Here, we assessed whether inhibition of cholesterol synthesis under these relatively hypocholesterolemic conditions may alter adrenal glucocorticoid output. Hypocholesterolemic apolipoprotein A1 (apoA1) knockout mice were administered high dose simvastatin twice daily for 3 days. Simvastatin treatment did not change plasma cholesterol levels or modify the adrenal expression levels of genes involved in cholesterol metabolism. However, simvastatin treatment lowered basal plasma levels of the primary glucocorticoid corticosterone (-62%; p < 0.05). Upon injection with adrenocorticotropic hormone, control-treated apoA1 knockout mice already showed only a mild increase in plasma corticosterone levels, indicative of relative glucocorticoid insufficiency. Importantly, simvastatin treatment further diminished the adrenal glucocorticoid response to adrenocorticotropic hormone exposure (two-way ANOVA p < 0.05 for treatment). Peak corticosterone levels were 49% lower (p < 0.01) upon simvastatin treatment. We have shown that simvastatin treatment aggravates the glucocorticoid insufficiency associated with hypocholesterolemia in mice. Our data suggest that (1) HMG-CoA reductase activity controls the adrenal steroidogenic capacity under hypocholesterolemic conditions and (2) imply that it might be important to monitor adrenal function in humans subjected to statin-based treatments aimed at achieving sub-physiological LDL-cholesterol levels, as these may potentially execute a negative impact on the glucocorticoid function in humans.

1 November 2018 in Atherosclerosis
Verified
Journal Article
Closed access
RSRonald J. van der Sluis
Ronald J. van der Sluis
RVRobin A.F. Verwilligen
Robin A.F. Verwilligen
ZLZsuzsanna Lendvai
Zsuzsanna Lendvai
RWRobbert Wever
Robbert Wever
Menno HoekstraMenno Hoekstra
Menno Hoekstra
MEMiranda Van Eck
Miranda Van Eck